Page last updated: 2024-10-24

negative regulation of ubiquitin protein ligase activity

Definition

Target type: biologicalprocess

Any process that stops, prevents or reduces the frequency, rate or extent of ubiquitin protein ligase activity. [GO_REF:0000059, GOC:dph, GOC:tb, GOC:TermGenie, PMID:26216882]

Negative regulation of ubiquitin protein ligase activity is a complex process that involves a variety of mechanisms to control the activity of ubiquitin ligases, which are enzymes responsible for attaching ubiquitin molecules to target proteins. Ubiquitination is a post-translational modification that can regulate a wide range of cellular processes, including protein degradation, signal transduction, and DNA repair.

To ensure proper cellular function, the activity of ubiquitin ligases must be tightly controlled. This control is achieved through a variety of mechanisms, including:

1. **Regulation of Ubiquitin Ligase Expression:** The levels of ubiquitin ligases can be controlled by transcriptional and translational regulation. This can involve factors like transcription factors, microRNAs, and post-translational modifications.

2. **Inhibition by Specific Inhibitors:** Some proteins act as specific inhibitors of ubiquitin ligases. These inhibitors can bind to the active site of the ligase, preventing it from interacting with its substrate.

3. **Regulation by Post-Translational Modifications:** Ubiquitin ligases themselves can be modified by ubiquitination, phosphorylation, or acetylation. These modifications can alter their activity and stability.

4. **Formation of Multi-protein Complexes:** Ubiquitin ligases often operate within larger complexes, interacting with other proteins that can either activate or inhibit their activity.

5. **Spatial Regulation:** Ubiquitin ligases can be localized to specific cellular compartments, where they can interact with specific substrates. This compartmentalization can further regulate their activity.

6. **Feedback Regulation:** Ubiquitination can be a self-regulating process. The ubiquitination of a substrate can lead to the degradation of the ubiquitin ligase itself, creating a negative feedback loop.

These mechanisms act in concert to ensure that ubiquitin ligases are only active when needed. Dysregulation of ubiquitin ligase activity can contribute to various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.'
"

Proteins (4)

ProteinDefinitionTaxonomy
60S ribosomal protein L11A eukaryotic-type large ribosomal subunit protein uL5 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P62913]Homo sapiens (human)
60S ribosomal protein L23A eukaryotic-type large ribosomal subunit protein uL14 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P62829]Homo sapiens (human)
40S ribosomal protein S7A small ribosomal subunit protein eS7 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P62081]Homo sapiens (human)
60S ribosomal protein L5A eukaryotic-type large ribosomal subunit protein uL18 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P46777]Homo sapiens (human)

Compounds (2)

CompoundDefinitionClassesRoles
gentamicin sulfate
PF-06446846PF-06446846 : A triazolopyridine that is 3H-[1,2,3]triazolo[4,5-b]pyridine substituted by a 4-{(3-chloropyridin-2-yl)[(3R)-piperidin-3-yl]carbamoyl}phenyl group at position 3. It is a potent inhibitor of PCSK9.

PF-06446846: inhibits translation of PCSK9 ;structure in first source
benzamides;
monochloropyridine;
piperidines;
tertiary carboxamide;
triazolopyridine
antilipemic drug;
EC 3.4.21.61 (kexin) inhibitor